JCM, Vol. 6, Pages 98: Production and Use of Hymenolepis diminuta Cysticercoids as Anti-Inflammatory Therapeutics

JCM, Vol. 6, Pages 98: Production and Use of Hymenolepis diminuta Cysticercoids as Anti-Inflammatory Therapeutics

Journal of Clinical Medicine doi: 10.3390/jcm6100098

Authors: Kendra Smyth Claire Morton Amanda Mathew Sahil Karuturi Cliff Haley Min Zhang Zoie Holzknecht Chelsea Swanson Shu Lin William Parker

Helminthic therapy has shown considerable promise as a means of alleviating some inflammatory diseases that have proven resistant to pharmaceutical intervention. However, research in the field has been limited by a lack of availability to clinician scientists of a helminth that is relatively benign, non-communicable, affordable, and effectively treats disease. Previous socio-medical studies have found that some individuals self-treating with helminths to alleviate various diseases are using the rat tapeworm (cysticercoid developmental stage of Hymenolepis diminuta; HDC). In this study, we describe the production and use of HDCs in a manner that is based on reports from individuals self-treating with helminths, individuals producing helminths for self-treatment, and physicians monitoring patients that are self-treating. The helminth may fit the criteria needed by clinical scientists for clinical trials, and the methodology is apparently feasible for any medical center to reproduce. It is hoped that future clinical trials using this organism may shed light on the potential for helminthic therapy to alleviate inflammatory diseases. Further, it is hoped that studies with HDCs may provide a stepping stone toward population-wide restoration of the biota of the human body, potentially reversing the inflammatory consequences of biota depletion that currently affect Western society.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2yNOHE7
via IFTTT